keep away from moisture
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Motixafortide (BKT140 4-fluorobenzoyl) is an antagonist of CXCR4 (IC50: 1 nM).
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
25 mg | 5 days | $ 747.00 | |
50 mg | 5 days | $ 1,190.00 |
Description | Motixafortide (BKT140 4-fluorobenzoyl) is an antagonist of CXCR4 (IC50: 1 nM). |
Targets&IC50 | CXCR4:1 nM |
In vitro | Motixafortide (BKT140) exhibits selective toxicity against AmL and MM cells by specifically inducing CXCR4-dependent and apoptotic cell death in these leukemia and multiple myeloma (MM) cell types. Additionally, treatment with Motixafortide (BKT140) counteracts the IL-6 dependent proliferation and survival observed in ARH77 MM cells. |
In vivo | Treatment with Motixafortide (BKT140) results in reduced size and weight of tumors in animals, alongside increased necrotic areas and elevated apoptotic scores[2]. Additionally, subcutaneous administration of Motixafortide (BKT140) markedly diminishes the growth of human acute myeloid leukemia and multiple myeloma xenografts in a dose-dependent fashion. |
Synonyms | BL-8040, BKT140 (4-fluorobenzoyl), TF14016 |
Molecular Weight | 2159.52 |
Formula | C97H144FN33O19S2 |
CAS No. | 664334-36-5 |
keep away from moisture
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 36 mg/mL (16.67 mM)
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Motixafortide 664334-36-5 Autophagy GPCR/G Protein Immunology/Inflammation CXCR BL8040 BL-8040 BL 8040 4-fluorobenzoyl TF-14016 TF 14016 BKT 140 BKT140 (4-fluorobenzoyl) TF14016 BKT140 BKT-140 inhibitor inhibit